Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vikas Prasad

Showing results (11-20 of 131) with videos related to

Pageof 14
Sort By:
Frontiers of Hormone Research|August 26, 2015
Peptide Receptor Radionuclide Therapy of Neuroendocrine TumorsLisa Bodei, Mark Kidd, Vikas Prasad, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|July 19, 2023
New horizon of radiopharmaceuticals in management of neuroendocrine tumorsAdeel Haq, Sampanna Rayamajhi, Maria Rosana Ponisio, et al.
Clinical Nuclear Medicine|March 7, 2023
Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory GlioblastomaStuart More, Thurandie Naiker, Nihaad Jacobs, et al.
International Journal of Molecular Imaging|November 29, 2011
Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CTSowon Oh, Vikas Prasad, Dong Soo Lee, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?Harshad R Kulkarni, Vikas Prasad, Christiane Schuchardt, et al.
Seminars in Nuclear Medicine|November 7, 2024
Current and Future Perspectives of PDL1 PET and SPECT ImagingIndraja D Dev, Ameya D Puranik, Baljinder Singh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 14, 2016
Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau diseaseVikas Prasad, Nikolaus Tiling, Timm Denecke, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|April 10, 2015
Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatmentAlexander D J Baur, Marianne Pavel, Vikas Prasad, et al.
PET Clinics|May 10, 2016
PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and MetabolismVikas Prasad, Valentina Ambrosini, Abass Alavi, et al.
PET Clinics|May 10, 2016
PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and MetabolismVikas Prasad, Valentina Ambrosini, Abass Alavi, et al.
Pageof 14

Showing results (11-20 of 131) with videos related to

Sort By:
Pageof 14
Frontiers of Hormone Research|August 26, 2015
Peptide Receptor Radionuclide Therapy of Neuroendocrine TumorsLisa Bodei, Mark Kidd, Vikas Prasad, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|July 19, 2023
New horizon of radiopharmaceuticals in management of neuroendocrine tumorsAdeel Haq, Sampanna Rayamajhi, Maria Rosana Ponisio, et al.
Clinical Nuclear Medicine|March 7, 2023
Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory GlioblastomaStuart More, Thurandie Naiker, Nihaad Jacobs, et al.
International Journal of Molecular Imaging|November 29, 2011
Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CTSowon Oh, Vikas Prasad, Dong Soo Lee, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?Harshad R Kulkarni, Vikas Prasad, Christiane Schuchardt, et al.
Seminars in Nuclear Medicine|November 7, 2024
Current and Future Perspectives of PDL1 PET and SPECT ImagingIndraja D Dev, Ameya D Puranik, Baljinder Singh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 14, 2016
Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau diseaseVikas Prasad, Nikolaus Tiling, Timm Denecke, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|April 10, 2015
Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatmentAlexander D J Baur, Marianne Pavel, Vikas Prasad, et al.
PET Clinics|May 10, 2016
PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and MetabolismVikas Prasad, Valentina Ambrosini, Abass Alavi, et al.
PET Clinics|May 10, 2016
PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and MetabolismVikas Prasad, Valentina Ambrosini, Abass Alavi, et al.
Pageof 14